Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.54 |
| ▸ | CTSA | P10619 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.41 |
| ▸ | STK10 | O94804 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8617145 | 0.85 | ERN1 (0.53) | ERN1CTSAS1PR5FFAR1PPARD | |
| SCHEMBL21162496 | 0.85 | ERN1 (0.59) | ERN1CTSAS1PR5FFAR1PPARD | |
| SCHEMBL8619252 | 0.85 | ERN1 (0.53) | ERN1CTSAS1PR5FFAR1PPARD | |
| SCHEMBL10093047 | 0.84 | ERN1 (0.55) | ERN1CTSAS1PR5FFAR1PPARD | |
| SCHEMBL9195885 | 0.83 | MAOB (0.56) | ERN1CTSAFFAR1PPARDMRGPRX4 | |
| SCHEMBL8613876 | 0.82 | ERN1 (0.51) | ERN1CTSAFFAR1PPARDMRGPRX4 | |
| SCHEMBL8611236 | 0.82 | ERN1 (0.51) | ERN1CTSAS1PR5FFAR1PPARD | |
| SCHEMBL8993210 | 0.82 | ERN1 (0.56) | ERN1CTSAS1PR5FFAR1PPARD | |
| SCHEMBL8612029 | 0.81 | ERN1 (0.52) | ERN1CTSAS1PR5FFAR1PPARD | |
| SCHEMBL8993237 | 0.81 | ERN1 (0.58) | ERN1CTSAS1PR5FFAR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | ERN1 3361/4885CTSA 1878/4885S1PR5 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.